Skip to main content
. 2021 Oct 26;13(21):5353. doi: 10.3390/cancers13215353

Table 1.

Association of SST1 demethylation with CRC genotype and phenotype.

Parameter Not Demethylated SST1 ΔRDL < 1.0 Moderately Demethylated
SST1 ΔRDL > 1.0 & < 3.0
Strongly Demethylated SST1 ΔRDL > 3.0 Fisher’s Test p-Value
Gender Women (n = 59) Women (n = 6) Women (n = 2) p1 = 0.19
Men (n = 64) Men (n = 12) Men (n = 5) p2 = 0.46
Age <66 y/o (n = 57) <66 y/o (n = 10) <66 y/o (n = 5) p1 = 0.27
>66 y/o (n = 66) >66 y/o (n = 8) >66 y/o (n = 2) p2 = 0.27
Ethnic Caucasian (n = 94) Caucasian (n = 9) Caucasian (n = 3) p1 = 0.05
Afr.Am. (n = 18) Afr.Am. (n = 6) Afr.Am. (n = 1) p2 = 0.58
Tumor Location Proximal (n = 69) Proximal (n = 10) Proximal (n = 2) p1 = 0.38
Distal (n = 50) Distal (n = 8) Distal (n = 5) p2 = 0.24
Dukes’ stage IS-A-B (n = 52) IS-A-B (n = 9) IS-A-B (n = 4) p1 = 0.39
C-D-M (n = 71) C-D-M (n = 9) C-D-M (n = 3) p2 = 0.70
MSI status MSS (n = 102) MSS (n = 17) MSS (n = 6) p1 = 0.37
MSI (n = 21) MSI (n = 1) MSI (n = 1) p2 = 1.00
TP53 WT (n = 44) WT (n = 5) WT (n = 0) p1 = 0.0037 **
MUT (n = 32) MUT (n = 11) MUT (n = 7) p2 = 0.012 *
KRAS WT (n = 75) WT (n = 12) WT (n = 7) p1 = 0.18
MUT (n = 48) MUT (n = 6) MUT (n = 0) p2 = 0.048 *
BRAF WT (n = 112) WT (n = 16) WT (n = 4) p1 = 0.25
MUT (n = 10) MUT (n = 2) MUT (n = 2) p2 = 0.10

p1: Fisher’s test p-value comparing not-demethylated tumors vs. the rest (demethylated and strongly demethylated). p2: Fisher’s test p-value comparing strongly demethylated tumors vs. the rest. *: p-value < 0.05. **: p-value < 0.01. In parenthesis, the number of informative cases in each category. In Ethnic, Afr.Am.: African American. In Duke’s stage, tumors were grouped into in situ (IS, n = 1), Duke’s A (n = 7) and Duke’s B (B, n = 54) vs. Duke’s C (n = 58), Duke’s D (n = 23) and metastases (M, n = 2). WT: wild-type. MUT: mutant. Some of the total number of samples do not match the total 148 cases sample due to incomplete information.